GSK (LSE:GSK) has delivered share price gains of 9% over the past month and 16% in the past 3 months, reflecting steady ...

The China National Medical Products Administration (NMPA) has approved Shingrix (GSK's Recombinant Zoster Vaccine or RZV) for ...

Indonesia relocates residents due to Caesium-137 contamination; New York and California support Planned Parenthood against federal funding cuts; English doctors strike for job security and pay; US ...

The FDA has approved belantamabmafodotin (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd)for the ...

The FDA approved of Blenrep in combination with bortezomib and dexamethasone (BVd) for adults with relapsed or refractory multiple myeloma who have received at least two prior therapies.

GSK tried again with the combination regimens, and two separate Phase 3 trials yielded promising results in 2024. In the ...

The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain ...

GSK's London-listed shares fell about 2% on Friday after the U.S. Food and Drug Administration approved only one of two ...

FDA approves GSK's Blenrep combo for relapsed multiple myeloma, showing 51% reduced death risk and tripled progression-free survival in Phase 3 trial.

GSK won approval from the U.S. Food and Drug Administration for blood-cancer drug Blenrep, paving the way for a return to the market of a medicine the company sees as a potential blockbuster.

Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a ...

The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...